Citigroup’s Aratana Therapeutics, Inc. PETX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-15,217
Closed -$78K 7958
2019
Q2
$78K Buy
15,217
+1,946
+15% +$8.75K ﹤0.01% 6097
2019
Q1
$48K Buy
13,271
+1,145
+9% +$4.96K ﹤0.01% 6383
2018
Q4
$74K Buy
12,126
+53
+0.4% +$323 ﹤0.01% 5911
2018
Q3
$70K Buy
12,073
+11,173
+1,241% +$55.8K ﹤0.01% 6238
2018
Q2
$4K Sell
900
-5,398
-86% -$27.2K ﹤0.01% 7405
2018
Q1
$27K Buy
6,298
+5,045
+403% +$22.5K ﹤0.01% 6584
2017
Q4
$7K Sell
1,253
-1,050
-46% -$6.42K ﹤0.01% 7167
2017
Q3
$14K Buy
2,303
+1,301
+130% +$8.23K ﹤0.01% 6595
2017
Q2
$7K Sell
1,002
-6,069
-86% -$37.3K ﹤0.01% 6666
2017
Q1
$37K Sell
7,071
-38,186
-84% -$258K ﹤0.01% 5903
2016
Q4
$325K Buy
45,257
+28,996
+178% +$234K ﹤0.01% 4830
2016
Q3
$152K Buy
16,261
+9,624
+145% +$79.9K ﹤0.01% 4888
2016
Q2
$42K Sell
6,637
-24,444
-79% -$157K ﹤0.01% 5680
2016
Q1
$172K Buy
31,081
+22,677
+270% +$85.3K ﹤0.01% 5232
2015
Q4
$48K Buy
8,404
+6,308
+301% +$41.7K ﹤0.01% 5972
2015
Q3
$18K Sell
2,096
-2,532
-55% -$42.8K ﹤0.01% 6118
2015
Q2
$70K Sell
4,628
-1,589
-26% -$22.9K ﹤0.01% 5274
2015
Q1
$100K Sell
6,217
-6,120
-50% -$109K ﹤0.01% 5028
2014
Q4
$220K Buy
12,337
+10,775
+690% +$134K ﹤0.01% 4605
2014
Q3
$16K Buy
1,562
+1,356
+658% +$16.4K ﹤0.01% 6038
2014
Q2
$3K Sell
206
-1,252
-86% -$17.7K ﹤0.01% 6677
2014
Q1
$27K Sell
1,458
-692
-32% -$13.9K ﹤0.01% 5872
2013
Q4
$41K Buy
+2,150
New +$43.6K ﹤0.01% 5818

Other funds holding PETX

Citigroup's PETX Position: Q3 2019 in Review

Citigroup sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 15,217 shares — an estimated $78K sold.

Citigroup first reported a position in PETX in Q4 2013 and held it in 23 quarters. The position peaked at $325K in Q4 2016. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • Citigroup reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Citigroup sold 15,217 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $78K.
  • Citigroup first reported a position in Aratana Therapeutics, Inc. in Q4 2013 and held it in 23 quarters.
  • Citigroup's Aratana Therapeutics, Inc. position peaked at $325K in Q4 2016.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Citigroup's 13F filing for Q3 2019, filed 8 Nov 2019.